Compare Stocks: NRXP, SPRY, EOLS, and OVID

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EOLS Evolus	$9.05 -0.1%	$7.22	$3.86 ▼ $9.15	$598.42M	1.42	1.20 million shs	734,215 shs
NRXP NRx Pharmaceuticals	$3.43 -0.9%	$3.69	$1.62 ▼ $5.05	$149.80M	2.19	1.12 million shs	236,416 shs
OVID Ovid Therapeutics	$2.78 +2.6%	$2.61	$1.12 ▼ $3.11	$529.26M	0.24	1.46 million shs	1.36 million shs
SPRY ARS Pharmaceuticals	$5.67 -2.6%	$6.53	$4.91 ▼ $13.15	$578.78M	1.05	1.76 million shs	1.09 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EOLS Evolus	-0.11%	+1.91%	+47.88%	+35.68%	+22.63%
NRXP NRx Pharmaceuticals	-0.87%	-5.25%	+12.46%	-17.15%	+31.92%
OVID Ovid Therapeutics	+2.58%	-5.12%	+9.45%	+15.83%	+109.02%
SPRY ARS Pharmaceuticals	-2.58%	-5.97%	+6.58%	-33.76%	-47.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EOLS Evolus	$9.05 -0.1%	$7.22	$3.86 ▼ $9.15	$598.42M	1.42	1.20 million shs	734,215 shs
NRXP NRx Pharmaceuticals	$3.43 -0.9%	$3.69	$1.62 ▼ $5.05	$149.80M	2.19	1.12 million shs	236,416 shs
OVID Ovid Therapeutics	$2.78 +2.6%	$2.61	$1.12 ▼ $3.11	$529.26M	0.24	1.46 million shs	1.36 million shs
SPRY ARS Pharmaceuticals	$5.67 -2.6%	$6.53	$4.91 ▼ $13.15	$578.78M	1.05	1.76 million shs	1.09 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EOLS Evolus	-0.11%	+1.91%	+47.88%	+35.68%	+22.63%
NRXP NRx Pharmaceuticals	-0.87%	-5.25%	+12.46%	-17.15%	+31.92%
OVID Ovid Therapeutics	+2.58%	-5.12%	+9.45%	+15.83%	+109.02%
SPRY ARS Pharmaceuticals	-2.58%	-5.97%	+6.58%	-33.76%	-47.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EOLS Evolus	2.50	Moderate Buy	$14.50	60.22% Upside
NRXP NRx Pharmaceuticals	2.43	Hold	$34.50	905.83% Upside
OVID Ovid Therapeutics	2.89	Moderate Buy	$5.86	110.69% Upside
SPRY ARS Pharmaceuticals	2.50	Moderate Buy	$28.20	397.35% Upside

Current Analyst Ratings Breakdown

Latest NRXP, SPRY, EOLS, and OVID Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	OVID Ovid Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
8/26/2026	NRXP NRx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	NRXP NRx Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/25/2026	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
8/25/2026	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/17/2026	SPRY ARS Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/10/2026	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$10.00
8/5/2026	NRXP NRx Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/3/2026	OVID Ovid Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$7.00 ➝ $9.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EOLS Evolus	$297.18M	2.01	N/A	N/A	($0.47) per share	-19.26
NRXP NRx Pharmaceuticals	$1.23M	120.75	N/A	N/A	N/A	∞
OVID Ovid Therapeutics	$7.25M	74.89	N/A	N/A	$1.07 per share	2.60
SPRY ARS Pharmaceuticals	$84.28M	6.69	N/A	N/A	$0.13 per share	43.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EOLS Evolus	-$51.64M	-$0.52	N/A	113.13	N/A	-10.85%	N/A	-13.00%	11/4/2026 (Estimated)
NRXP NRx Pharmaceuticals	-$28.62M	-$0.55	N/A	N/A	N/A	-691.81%	N/A	-63.92%	11/13/2026 (Estimated)
OVID Ovid Therapeutics	-$17.41M	-$0.31	N/A	N/A	N/A	-240.11%	-23.64%	-20.52%	11/11/2026 (Estimated)
SPRY ARS Pharmaceuticals	-$171.30M	-$2.18	N/A	N/A	N/A	-184.24%	-256.67%	-69.63%	11/9/2026 (Estimated)

Latest NRXP, SPRY, EOLS, and OVID Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q2 2026	NRXP NRx Pharmaceuticals	-$0.1067	-$0.44	-$0.3333	-$0.44	$1.33 million	$1.10 million
8/13/2026	Q2 2026	OVID Ovid Therapeutics	-$0.1150	-$0.08	+$0.0350	-$0.08	$0.02 million	$0.73 million
8/13/2026	Q2 2026	SPRY ARS Pharmaceuticals	-$0.4777	-$0.63	-$0.1523	-$0.63	$31.32 million	$33.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EOLS Evolus	N/A	1.70	1.28
NRXP NRx Pharmaceuticals	N/A	0.86	0.86
OVID Ovid Therapeutics	0.05	12.39	12.39
SPRY ARS Pharmaceuticals	13.72	3.48	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EOLS Evolus	90.69%
NRXP NRx Pharmaceuticals	4.27%
OVID Ovid Therapeutics	72.24%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
EOLS Evolus	5.00%
NRXP NRx Pharmaceuticals	6.40%
OVID Ovid Therapeutics	7.00%
SPRY ARS Pharmaceuticals	33.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EOLS Evolus	170	66.05 million	62.75 million	Optionable
NRXP NRx Pharmaceuticals	2	43.30 million	40.53 million	Optionable
OVID Ovid Therapeutics	60	195.30 million	181.63 million	Optionable
SPRY ARS Pharmaceuticals	90	99.45 million	65.83 million	Optionable

NRXP, SPRY, EOLS, and OVID Headlines

Recent News About These Companies

ROSEN, A LONGSTANDING LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY

3 hours ago | newsfilecorp.comN

Kaplan Fox Continues to Remind ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors of the Lead Plaintiff Deadline on October 5, 2026

September 3 at 9:21 PM | theglobeandmail.com

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

September 3 at 7:41 PM | globenewswire.com

Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (SPRY) Investors to Seek Counsel Before the October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action

September 3 at 1:11 PM | newsfilecorp.comN

Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm

September 3 at 12:00 PM | globenewswire.com

SPRY UPCOMING DEADLINE: SueWallSt Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class Action - Contact the Firm

September 3 at 10:07 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY

September 3 at 10:00 AM | prnewswire.com

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY

September 2 at 11:21 PM | newsfilecorp.comN

ARS Stock Drop: Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Against ARS Pharmaceuticals Inc.

September 2 at 3:36 PM | newsfilecorp.comN

SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky

September 2 at 10:07 AM | prnewswire.com

Kaplan Fox Alerts Investors of a Securities Class Action Against ARS Pharmaceuticals Inc. (SPRY) - Deadline is October 5, 2026

September 2 at 10:00 AM | newsfilecorp.comN

Bank of America Corp DE Cuts Stake in ARS Pharmaceuticals, Inc. $SPRY

September 2 at 3:13 AM | marketbeat.com

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

September 1 at 11:58 PM | prnewswire.com

Kaplan Fox Continues to Alert Investors of a Securities Class Action Deadline on October 5, 2026 Against ARS Pharmaceuticals Inc. (NASDAQ: SPRY)

September 1 at 10:26 PM | theglobeandmail.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY

September 1 at 5:15 PM | globenewswire.com

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

September 1 at 4:01 PM | globenewswire.com

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

September 1 at 10:32 AM | globenewswire.com

SPRY DEADLINE: SueWallSt Reminds ARS Pharmaceuticals Inc. Investors of Upcoming Securities Class Action Deadline

September 1 at 10:17 AM | globenewswire.com

SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

September 1 at 8:35 AM | newsfilecorp.comN

BlackRock Inc. Invests $42.54 Million in ARS Pharmaceuticals, Inc. $SPRY

September 1 at 3:21 AM | marketbeat.com

ROSEN, REGARDED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

August 31, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXP, SPRY, EOLS, and OVID Company Descriptions

Evolus NASDAQ:EOLS

$9.05 -0.01 (-0.11%)

As of 09/3/2026 04:00 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

NRx Pharmaceuticals NASDAQ:NRXP

$3.43 -0.03 (-0.87%)

As of 09/3/2026 04:00 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Ovid Therapeutics NASDAQ:OVID

$2.78 +0.07 (+2.58%)

As of 09/3/2026 04:00 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

ARS Pharmaceuticals NASDAQ:SPRY

$5.67 -0.15 (-2.58%)

As of 09/3/2026 04:00 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRXP, SPRY, EOLS, and OVID Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRXP, SPRY, EOLS, and OVID Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRXP, SPRY, EOLS, and OVID Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXP, SPRY, EOLS, and OVID Company Descriptions

Evolus NASDAQ:EOLS

NRx Pharmaceuticals NASDAQ:NRXP

Ovid Therapeutics NASDAQ:OVID

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRXP, SPRY, EOLS, and OVID Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRXP, SPRY, EOLS, and OVID Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRXP, SPRY, EOLS, and OVID Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXP, SPRY, EOLS, and OVID Company Descriptions

Evolus NASDAQ:EOLS

NRx Pharmaceuticals NASDAQ:NRXP

Ovid Therapeutics NASDAQ:OVID

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools